secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001193125-23-209064
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spero reports Q2 loss $11.9M; FDA SPA for tebipenem HBr P3 trial
----------------------------------------------------------------

- Net loss $11.9M ($0.23/sh) vs $28.7M ($0.87) in Q2 2022; revenue $2.7M.
- FDA SPA agreement on design of Phase 3 PIVOT-PO trial for tebipenem HBr; first patient expected Q4 2023.
- Sath Shukla appointed President and CEO effective Aug 1; succeeds Ankit Mahadevia (now Chairman).
- Cash $77.7M + $30M GSK milestone; cash runway into H2 2025.
- SPR720 Phase 2 trial enrolling, topline data H2 2024; SPR206 IND planned Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312523209064/0001193125-23-209064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312523209064/d494367d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-209064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer